VBI Vaccines (NASDAQ:VBIV) Research Coverage Started at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of VBI Vaccines (NASDAQ:VBIV) in a research note issued on Friday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

VBI Vaccines Stock Down 1.5 %

Shares of VBI Vaccines stock opened at $0.59 on Friday. VBI Vaccines has a 1-year low of $0.45 and a 1-year high of $3.47. The firm’s 50-day moving average price is $0.61 and its two-hundred day moving average price is $0.62.

VBI Vaccines (NASDAQ:VBIV) last released its quarterly earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.02). VBI Vaccines had a negative return on equity of 525.42% and a negative net margin of 881.79%. The business had revenue of $1.21 million for the quarter, compared to the consensus estimate of $2.85 million. Research analysts anticipate that VBI Vaccines will post -1.23 earnings per share for the current fiscal year.

About VBI Vaccines

VBI Vaccines Inc, a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.